Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.

Armakolas A, Alevizopoulos N, Stathaki M, Petraki C, Agrogiannis G, Samiotaki M, Panayotou G, Chatzinikita E, Koutsilieris M

British journal of cancer20 Jun 2024Cited by 2 (Europe PMC)

PMID38902531PMCIDPMC11300853DOI10.1038/s41416-024-02713-8PepBankPUB-38902531

Source link PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MGF / PEG-MGF.

01AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Efficacy outcome
In SCID mice with prostate cancer tumours, anti-PEc monoclonal antibody treatment was associated with a significant decrease in tumour size (p < 0.0005).
In plain wordsIn mice with prostate tumours, an antibody against the Ec peptide was linked to smaller tumours.
Peptide
MGF / PEG-MGF
Outcome
DecreaseTumour size
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In vivo, anti-PEc MAb treatment was associated with a significant decrease in tumour size and metastases rate (p < 0.0005 in every case) by reversing the tumours mesenchymal phenotype.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253107
02AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Efficacy outcome
In SCID mice with prostate cancer tumours, anti-PEc monoclonal antibody treatment was associated with a significant decrease in the metastases rate (p < 0.0005).
In plain wordsIn mice with prostate tumours, an antibody against the Ec peptide was linked to fewer metastases.
Peptide
MGF / PEG-MGF
Outcome
DecreaseMetastases rate
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Tumor growth · Cancer
Source sentences
Summary
In vivo, anti-PEc MAb treatment was associated with a significant decrease in tumour size and metastases rate (p < 0.0005 in every case) by reversing the tumours mesenchymal phenotype.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253108
03AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Mechanism
In SCID mice with prostate cancer tumours, the anti-PEc antibody inhibited host stem cell mobilisation towards the tumour.
In plain wordsIn mice with prostate tumours, an antibody against the Ec peptide reduced the movement of host stem cells to the tumour.
Peptide
MGF / PEG-MGF
Outcome
DecreaseHost stem cell mobilisation toward the tumour
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Tumor growth · Cancer
Source sentences
Summary
It also inhibited host stem cell mobilisation towards the tumour, leading to apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253109
04AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Mechanism
In SCID mice with prostate cancer tumours, inhibition of host stem cell mobilisation by the anti-PEc antibody led to apoptosis.
In plain wordsIn mice with prostate tumours, an antibody against the Ec peptide led to tumour cell death.
Peptide
MGF / PEG-MGF
Outcome
IncreaseTumour apoptosis
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Tumor growth · Cancer
Source sentences
Summary
It also inhibited host stem cell mobilisation towards the tumour, leading to apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253110
05AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Pharmacokinetics
In SCID mice, the distribution of the anti-PEc antibody indicated tumour specificity.
In plain wordsIn mice, an antibody against the Ec peptide reached mainly the tumour.
Peptide
MGF / PEG-MGF
Outcome
Not applicableTissue distribution of the anti-PEc antibody
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Anti-PEc MAb assessment in respect to distribution and toxicity, indicated its tumour specificity
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253111
06AnimalNot a test of MGF / PEG-MGF aloneAnimal study (in vivo)Safety outcome
In SCID mice, the anti-PEc antibody showed a lack of toxicity.
In plain wordsIn mice, an antibody against the Ec peptide showed no toxicity.
Peptide
MGF / PEG-MGF
Outcome
No significant changeToxicity of the anti-PEc antibody
Study
mousen: not reported in source
SCID mice with prostate cancer cell tumours
Outcome group
Adverse events · Cancer
Source sentences
Summary
Anti-PEc MAb assessment in respect to distribution and toxicity, indicated its tumour specificity and lack of toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253112
07LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Efficacy outcome
In cell lines, anti-PEc monoclonal antibody treatment decreased cellular proliferation versus untreated cells (p < 0.0005).
In plain wordsIn cells, an antibody against the Ec peptide reduced cell growth compared with untreated cells.
Peptide
MGF / PEG-MGF
Outcome
DecreaseCellular proliferation
Study
n: not reported in source
Cancer and non-cancerous cell lines
Comparator
Untreated cell lines
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Anti-PEc MAb treatment led to a significant decrease in cellular proliferation, migration, and invasion compared to the untreated cell lines (p < 0.0005 in every case).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253101
08LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Efficacy outcome
In cell lines, anti-PEc monoclonal antibody treatment decreased cell migration versus untreated cells (p < 0.0005).
In plain wordsIn cells, an antibody against the Ec peptide reduced cell movement compared with untreated cells.
Peptide
MGF / PEG-MGF
Outcome
DecreaseCell migration
Study
n: not reported in source
Cancer and non-cancerous cell lines
Comparator
Untreated cell lines
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Anti-PEc MAb treatment led to a significant decrease in cellular proliferation, migration, and invasion compared to the untreated cell lines (p < 0.0005 in every case).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253102
09LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Efficacy outcome
In cell lines, anti-PEc monoclonal antibody treatment decreased cell invasion versus untreated cells (p < 0.0005).
In plain wordsIn cells, an antibody against the Ec peptide reduced cell invasion compared with untreated cells.
Peptide
MGF / PEG-MGF
Outcome
DecreaseCell invasion
Study
n: not reported in source
Cancer and non-cancerous cell lines
Comparator
Untreated cell lines
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Anti-PEc MAb treatment led to a significant decrease in cellular proliferation, migration, and invasion compared to the untreated cell lines (p < 0.0005 in every case).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253103
10LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism
In cell lines, the anti-PEc antibody effects were associated with downregulation of pERK1/2.
In plain wordsIn cells, the antibody against the Ec peptide was linked to lower pERK1/2.
Peptide
MGF / PEG-MGF
Outcome
DecreasepERK1/2 expression
Study
n: not reported in source
Cancer and non-cancerous cell lines
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Mechanistically, these effects were associated with the downregulation of pERK1/2 and vimentin and the upregulation of E-Cadherin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253104
11LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism
In cell lines, the anti-PEc antibody effects were associated with downregulation of vimentin.
In plain wordsIn cells, the antibody against the Ec peptide was linked to lower vimentin.
Peptide
MGF / PEG-MGF
Outcome
DecreaseVimentin expression
Study
n: not reported in source
Cancer and non-cancerous cell lines
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Mechanistically, these effects were associated with the downregulation of pERK1/2 and vimentin and the upregulation of E-Cadherin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253105
12LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Mechanism
In cell lines, the anti-PEc antibody effects were associated with upregulation of E-Cadherin.
In plain wordsIn cells, the antibody against the Ec peptide was linked to higher E-Cadherin.
Peptide
MGF / PEG-MGF
Outcome
IncreaseE-Cadherin expression
Study
n: not reported in source
Cancer and non-cancerous cell lines
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
Mechanistically, these effects were associated with the downregulation of pERK1/2 and vimentin and the upregulation of E-Cadherin.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-3890253106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.